| 1.43 0.03 (2.14%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.46 |
| Resists | First : | 1.79 | Second : | 2.1 |
| Pivot price | 1.45  |
|||
| Supports | First : | 1.27 | Second : | 1.06 |
| MAs | MA(5) : | 1.39  |
MA(20) : | 1.51 |
| MA(100) : | 1.83 |
MA(250) : | 1.6 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23 |
D(3) : | 17.7 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 3.81 | Low : | 0.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IBIO ] has closed above bottom band by 42.8%. Bollinger Bands are 47.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.47 - 1.47 | 1.47 - 1.48 |
| Low: | 1.3 - 1.3 | 1.3 - 1.31 |
| Close: | 1.42 - 1.43 | 1.43 - 1.44 |
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
Sat, 25 Jul 2026
Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO - MarketBeat
Fri, 24 Jul 2026
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Wed, 22 Jul 2026
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Sat, 18 Jul 2026
iBio Updates Governance Deadlines for 2026 Annual Meeting - The Globe and Mail
Fri, 17 Jul 2026
iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines - Stock Titan
Fri, 26 Jun 2026
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 4.547e+007 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 3,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.827e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 653 % |
| Return on Equity (ttm) | -34.5 % |
| Qtrly Rev. Growth | 300000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -48.89 |
| EBITDA (p.s.) | 236220 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.81 |
| Dividend | 0 |
| Forward Dividend | 4.69e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|